Abstract: The present invention provides a method for determining sensitivity of tumor cells to dasatinib by evaluating inhibitory capacity of a predetermined tyrosine kinase inhibitor in a measurement sample which is prepared from a biological sample containing tumor cells and a computer program.

Abstract: A method for assessing an efficacy of combination chemotherapy, comprising: a first obtaining process for obtaining a specific activity value of Cyclin Dependent Kinase (CDK) 1 and a specific activity value of CDK2 in a biological sample including a carcinoma cell collected from a cancer patient; a second obtaining process for obtaining a GST? expression level in the biological sample; and an assessment process for assessing the efficacy of the combination chemotherapy on the cancer patient based on the specific activity values of CDK1 and CDK2 obtained in the first obtaining process and the GST? expression level obtained in the second obtaining process.

Abstract: The present invention provides a method for determining sensitivity of the tumor cells to an EGFR and/or HER2 inhibitor by evaluating inhibitory capacity of an Src inhibitor in a sample for measuring tyrosine kinase activity which is prepared from a biological sample containing tumor cells, a computer program and a method for determining effectiveness.

Abstract: A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of the comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.

Abstract: A method for predicting an effectiveness of chemotherapy is described. The method comprises a comparing step and a predicting step. The comparing step is a step of comparing a threshold value with a parameter of a cyclin dependent kinase (CDK) included in a sample containing a tumor cell obtained from a human patient. The predicting step is a step of predicting the effectiveness based on a comparison result of said comparing step. Above stated parameter is selected from the group consisting of an activity, an expression level, and a ratio of activity to expression level.